High-mobility group A (HMGA) proteins and breast cancer

Breast Care

Volumn 5, Issue 2, 2010, Pages 81-85

  Peluso, Silvia ^a   Chiappetta, Gennaro ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Blood samples; Breast cancer; HMGA; Prognostic factors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; HIGH MOBILITY GROUP A PROTEIN;

BINDING AFFINITY; BREAST CANCER; CARCINOGENESIS; CELL DIFFERENTIATION; EMBRYO DEVELOPMENT; GENE FUNCTION; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; GENE STRUCTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; IMMUNOPHENOTYPING; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW;

EID: 77952849736     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000297717     Document Type: Review

References (36)

1. Bustin M: Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci 2001;26:152-153.
2. Cleynen I, Van De Ven WJ: The HMGA proteins: A myriad of functions. Int J Oncol 2008;32:289-305.
3. Friedmann M, Holth LT, Zoghbi HY, Reeves R: Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993;21: 4259-4267.
4. Nagpal S, Ghosn C, DiSepio D, Molina Y, Sutter M, Klein ES, Chandraratna RA: Retinoid-dependent recruitment of a histone H1 displacement activity by retinoic acid receptor. J Biol Chem 1999;274: 22563-22568.
5. Thanos D, Du W, Maniatis T: The high mobility group protein HMG I(Y) is an essential structural component of a virus-inducible enhancer complex. Cold Spring Harb Symp Quant Biol 1993;58:73-81.
6. Zhou X, Benson KF, Ashar HR, Chada K: Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C. Nature 1995;376:771-774.
7. Chin MT, Pellacani A, Wang H, Lin SS, Jain MK, Perrella MA, Lee ME: Enhancement of serumresponse factor-dependent transcription and DNA binding by the architectural transcription factor HMG-I(Y). J Biol Chem 1998;27:9755-9760.
8. Zhao K, Käs E, Gonzalez E, Laemmli UK: SARdependent mobilization of histone H1 by HMGI/ Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J 1993;12:3237-3247.
9. Fusco A, Fedele M: Roles of the HMGA proteins in cancer. Nat Rev Cancer 2007;7:899-910.
10. Chiappetta G, Avantaggiato V, Visconti R, Fedele M, Battista S, Trapasso F, Merciai BM, Fidanza V, Giancotti V, Santoro M, Simeone A, Fusco A: High level expression of the HMGI (Y) gene during embryonic development. Oncogene 1996;5:2439-2446.
11. Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-242.
12. Narod S, Ford D, Devilee P, Barkardottir RB, Eyfjord J, Lenoir G, Serova O, Easton D, Goldgar D: Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet 1995;57:957-958.
13. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst 1999;91:943-949.
14. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer: Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
15. Marcus JN, Watson P, Page DL, Narod SA, Tonin P, Lenoir GM, Serova O, Lynch HT: BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997;44:275-277. (Pubitemid 27296388)
16. Armes JE, Egan AJ, Southey MC, Dite GS, Mc- Credie MR, Giles GG, Hopper JL, Venter DJ: The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-2345.
17. Liu WM, Guerra-Vladusic FK, Kurakata S, Lupu R, Kohwi-Shigematsu T: HMG-I(Y) recognizes base-unpairing regions of matrix attachment sequences and its increased expression is directly linked to metastatic breast cancer phenotype. Cancer Res 1999;59:5695-5703.
18. Chiappetta G, Botti G, Monaco M, Pasquinelli R, Pentimalli F, Di Bonito M, D'Aiuto G, Fedele M, Iuliano R, Palmieri EA, Pierantoni GM, Giancotti V, Fusco A: HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Can Res 2004;10:7637-7644.
19. Bernard-Gallon DJ, De Latour MP, Rio PG, Penault-Llorca FM, Favy DA, Hizel C, Chassagne J, Bignon YJ: Subcellular localization of BRCA1 protein in sporadic breast carcinoma with or without allelic loss of BRCA1 gene. Int J Oncol 1999;14: 653-661.
20. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A: Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000;21:147-151.
21. Rio PG, Maurizis JC, Peffault de Latour M, Bignon YJ, Bernard-Gallon DJ: Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene. Int J Cancer 1999;80:823-826.
22. Baldassarre G, Battista S, Belletti B, Thakur S, Pentimalli F, Trapasso F, Fedele M, Pierantoni G, Croce GM, Fusco A: Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol 2003;23: 2225-2238.
23. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S, Fusco A: Highmobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007;117:693-702.
24. Chiappetta G, Ottaiano A, Vuttariello E, Monaco M, Galdiero F, Gallipoli A, Pilotti S, Jodice G, Siranoush M, Colombo M, Ripamonti CB, Pallante PL, Radice P, Fusco A: HMGA1 protein expression in familial breast carcinoma patients. Eur J Cancer 2010;46:332-339.
25. Boo LM, Lin HH, Chung V, Zhou B, Louie SG, O'Reilly MA, Yen Y, Ann DK: High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damagedependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res 2005;65: 6622-6630.
26. Summer H, Li O, Bao Q, Zhan L, Peter S, Sathiyanathan P, Henderson D, Klonisch T, Goodman SD, Dröge P: HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage- induced cytotoxicity during chemotherapy. Nucleic Acids Res 2009;37:4371-4384.
27. Andres JL, Fan S, Turkel GJ, Wang JA, Twu NF, Yuan RQ, Lamszus K, Goldberg ID, Rosen EM: Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents. Oncogene 1998;16:2229-2241.
28. Berlingieri MT, Manfioletti G, Santoro M, Bandiera A, Visconti R, Giancotti V, Fusco A: Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545-1553.
29. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK: The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-23903.
30. Baldassarre G, Belletti B, Battista S, Nicoloso MS, Pentimalli F, Fedele M, Croce CM, Fusco A: HMGA1 protein expression sensitizes cells to cisplatin- induced cell death. Oncogene 2005;24:6809-6819.
31. Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M: Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 1989;46:318-322.
32. Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999;5
33. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, España P, Bonilla F: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999;59:3251-3256. (Pubitemid 29316030)
34. García JM, García V, Peña C, Domínguez G, Silva J, Diaz R, Espinosa P, Citores MJ, Collado M, Bonilla F: Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA 2008;14:1424-1432.
35. Sezer O, Langelotz C, Blohmer JU, Schmid P, Akrivakis K, Possinger K: Detection of HMGI-C in the peripheral blood of breast cancer patients. Eur J Cancer 2000;36:1944-1948.
36. Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O: Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer. Br J Cancer 2003;88:1406-1410.